Malignant Tumor of Lung, Poor Performance Status
Conditions
Keywords
Almonertinib, Non-Small Cells Lung Cancer, poor performance status
Brief summary
Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore, the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.
Detailed description
Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.In recent years, systemic treatments with good efficacy and low toxicity, such as gene-targeted therapy, anti-angiogenic therapy and immunotherapy, have largely replaced single chemotherapy, and have great potential to benefit from existing treatments for poor PS scores of advanced lung cancer patients can adopt more aggressive treatment strategies.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore,the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.
Interventions
DRUGAlmonertinib
Almonertinib Mesilate Tablets
Sponsors
Guangzhou Institute of Respiratory Disease
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group Assignment Almonertinib monotherapy
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up. 2. Male or female who is over 18 years old. 3. Malignant tumorsr proved by pathology. 4. NSCLC patients with EGFR mutation (19 deletion/21 L858R point mutation) or primary T790M mutation in pre-enrollment genetic testing. 5. PS score of 2-4; this score is caused by complications caused by the tumor and cannot be improved by any non-anti-tumor means. 6. Patients with brain metastases may be enrolled at the discretion of the investigator. 7. Appropriate organ system function.
Exclusion criteria
1. Patients who have previously used any antineoplastic drugs。 2. Small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer); 3. Genetic testing results in patients with rare EGFR genotypes (G719X, E709X, Del18 on exon 18, Ins19 on exon 19, Ins20, S768I on exon 20, and L861Q on exon 21). 4. Patients with other mutations (ALK, Ros-1, C-MET). 5. Imperfection of upper gastrointestinal physiology, or absorption disorder syndrome, or inability to tolerate oral drugs, or active peptic ulcer; 6. Participated in other clinical trials within 4 weeks before the start of the study; 7. patients with hypertension who cannot control well through single antihypertensive medication (systolic blood pressure \> 140mmhg, diastolic blood pressure \> 90mmhg), myocardial ischemia or myocardial infarction, arrhythmia (including QT interval \> 440 ms) or cardiac insufficiency; 8. Allergic to any ingredient in the drug; 9. Patients with abnormal coagulation function, receiving thrombolysis or anticoagulation therapy, bleeding tendency or have clear gastrointestinal bleeding concerns; 10. Hyperactive/venous thrombosis events, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism occurred in 6 months before the start of the study; 11. Wound or fracture has not been healed for a long time; 12. urinary protein was greater than ++ and 24-hour urinary protein quantification #1.0 g. 13. Severe or uncontrolled infections; 14. Substance abuse or mental disorder; 15. Objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe impairment of pulmonary function; 16. Immunodeficiency, including being HIV-positive, or having other acquired, congenital immunodeficiency diseases, or having a history of organ transplantation; 17. Other malignant tumors within 5 years, except cured basal cell carcinoma of the skin and orthotopic carcinoma of the cervix; 18. Who have received VEGFR inhibitors, such as sorafenib and sunitinib, etc.; 19. pregnant or lactating women; 20. the researchers considered it unsuitable for inclusion。
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 24 months | Objective Response Rate |
| Time of PS score change from 2~4 to 1 | 6 months | Time of performance status score change from 2\ 4 to 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 24 months | Median progression-free survival |
| OS | from baseline until death due to any cause, up to a maximum of approximately 4years | Median overall survival |
| DCR | 24 months | Disease control rate |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety: Dose-limiting toxicities | from the screening period to 28 days after treatment completion | Any level 3 or greater toxicity |
Countries
China
Contacts
Primary ContactZhou Chengzhi, MD
Outcome results
None listed